The 8,323-patient cardiovascular outcomes trial missed its primary endpoint, showing that lowering lipoprotein(a) did not translate into a statistically significant reduction in major cardiovascular events.
Key Takeaways
- Novartis reported that the Phase 3 Lp(a)HORIZON trial of pelacarsen failed to meet its primary endpoint in patients with elevated lipoprotein(a) and established cardiovascular disease.
- Pelacarsen lowered Lp(a), but the trial did not demonstrate a statistically significant reduction in 4-point major adverse cardiovascular events versus placebo.
- The current announcement contains topline results only, so detailed event rates, hazard ratios, subgroup analyses and the exact magnitude of Lp(a) lowering still need to be evaluated when the full dataset is presented. (Novartis topline)
Data Snapshot
| Item | Details |
|---|---|
| Drug | Pelacarsen |
| Companies | Novartis / Ionis Pharmaceuticals |
| Modality | Antisense oligonucleotide |
| Target | LPA mRNA |
| Indication | Elevated Lp(a) with established cardiovascular disease |
| Trial | Lp(a)HORIZON |
| Phase | Phase 3 |
| Participants | 8,323 |
| Design | Randomized, double-blind, placebo-controlled |
| Primary endpoint | 4-point MACE |
| Biological effect | Lp(a) lowered |
| Primary result | Endpoint not met |
| Disclosure status | Topline results only |
The Phase 3 Lp(a)HORIZON trial enrolled 8,323 patients with elevated lipoprotein(a) and established cardiovascular disease to test whether pelacarsen could reduce major cardiovascular events.
What Happened
On September 4, 2026, Novartis announced that pelacarsen failed to meet the primary endpoint in the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial.
The study enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease and evaluated pelacarsen on top of contemporary standard cardiovascular therapy.
The primary endpoint was 4-point major adverse cardiovascular events (MACE), defined as:
- cardiovascular death
- non-fatal myocardial infarction
- non-fatal stroke
- urgent coronary revascularization requiring hospitalization
Pelacarsen lowered Lp(a), but Lp(a)HORIZON did not demonstrate a statistically significant reduction in 4-point MACE versus placebo.
This distinction is important because the trial was designed to test a clinical-outcome hypothesis, not simply whether the drug could reduce the biomarker.
Novartis has so far disclosed topline results only. Detailed HORIZON data—including event rates, hazard ratios, subgroup analyses and the magnitude of Lp(a) lowering—have not yet been publicly presented and will need to be assessed when the full dataset is released.
Fierce Biotech highlighted the result as a major setback for pelacarsen while noting that it does not necessarily settle the broader Lp(a) therapeutic hypothesis, particularly as competing RNAi programs pursue deeper Lp(a) suppression. (Fierce Biotech)
Why It Matters
Lipoprotein(a), or Lp(a), is an inherited and independent cardiovascular risk factor. The LPA gene encodes apolipoprotein(a), which becomes part of the circulating Lp(a) particle.
Pelacarsen is an antisense oligonucleotide designed to target LPA mRNA in the liver, reducing apolipoprotein(a) production and lowering circulating Lp(a).
The therapeutic hypothesis was:
Pelacarsen → LPA mRNA ↓ → apo(a) ↓ → Lp(a) ↓ → cardiovascular events ↓
The Phase 3 result broke that expected chain at the final step:
Lp(a) ↓ → 4-point MACE ↓ was not demonstrated.
This does not prove that Lp(a) is biologically irrelevant. It shows that the degree and duration of Lp(a) lowering achieved with pelacarsen in this secondary-prevention population were not sufficient to produce a statistically significant reduction in the primary cardiovascular outcome.
Why did lowering Lp(a) fail to translate into fewer major cardiovascular events?
Read the BP Science explainer:
Why Lowering Lp(a) Wasn’t Enough: What Pelacarsen’s Phase 3 Failure Means
BP View
Pelacarsen’s failure matters because Lp(a)HORIZON was not simply testing whether a drug could lower Lp(a). It was testing whether pharmacological Lp(a) lowering could translate into fewer cardiovascular events in patients who already had established cardiovascular disease.
That makes the negative result scientifically important. Pelacarsen achieved biological target engagement, but the expected clinical benefit was not demonstrated. The key question now shifts from “Can Lp(a) be lowered?” to “How much lowering, for how long, and in which patients is required to reduce cardiovascular events?”
The competitive landscape now becomes more important. Next-generation RNAi programs from companies including Amgen and Eli Lilly have shown substantially deeper Lp(a) reductions in earlier-stage studies. Their cardiovascular outcomes trials will help determine whether the HORIZON result reflects a limitation of pelacarsen specifically or a broader challenge for the Lp(a)-lowering strategy.
For now, the interpretation should remain cautious because only topline data are available. The eventual event rates, hazard ratio, confidence intervals, subgroup analyses and achieved Lp(a) reduction will be essential to understanding why HORIZON failed and whether any patient subgroup showed a clinically meaningful signal.
In my view, pelacarsen validated Lp(a) as a pharmacologically modifiable target, but failed to validate its level of Lp(a) lowering as a sufficient cardiovascular-outcome strategy in the Phase 3 HORIZON population. The broader Lp(a) therapeutic hypothesis is therefore challenged, but not yet disproven.
Related Post
For another recent example of an RNA-targeted therapy reaching a decisive clinical outcome, read my previous analysis of Ionis’ Zanvastro approval in Alexander disease.
About BP
Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.
Have a different view on this analysis or something you’d like to discuss? Leave a comment — I’d be happy to hear your thoughts.
Leave a Reply